Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer

Sponsor
Peng Zhang
Study ID
NCT06755684
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Antineoplastic Agents
  • Bevacizumab
  • Carboplatin
  • EGFR
  • Locally Advanced Non-Small Cell Lung Cancer
  • Non-Small Cell Lung Cancer
  • Pemetrexed
  • Tyrosine Kinase Inhibitor

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Befotertinib combined Bevacizumab — DRUG
    Befotertinib combined Bevacizumab
  • Befotertinib combined platinum-based double chemotherapy — DRUG
    Befotertinib combined platinum-based double chemotherapy

Study Details

This study targeted patients with resectable stage II-IIIA non-small cell lung cancer with EGFR mutation

Key Dates

First listed
Jan 1, 2025
Start date
Nov 7, 2024
Status verified
Jan 2025
Primary completion
Dec 31, 2025
Completion
Dec 31, 2028

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Befotertinib combined Bevacizumab
    Befotertinib combined Bevacizumab
  • Experimental: Befotertinib combined platinum-based double chemotherapy
    Befotertinib combined platinum-based double chemotherapy

Primary Outcome Measure

Major pathologic response (MPR) [ Time Frame: up to 4 months ]

Central Contacts

Related Studies